type 1 and type 2 diabetes
Endocrinology · 2007–2018
5decisions
5medicines
3carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| insulin aspart Treatment of type 1 and type 2 diabetes mellitus in adults requiring bolus insulin therapy, delivered as subcutaneous injections or via external continuous… | Nov 2018 | Recommended | input received |
| insulin degludec with insulin aspart Treatment of adult patients with type 1 diabetes mellitus and type 2 diabetes mellitus requiring basal and prandial insulin to improve glycaemic control. | Nov 2017 | Not recommended | input received Australian Diabetes Society |
| insulin lispro Treatment of type 1 and type 2 diabetes mellitus in patients who require higher daily insulin doses of >20 U. | Nov 2017 | Recommended | none received |
| insulin glargine Treatment of adults with diabetes mellitus (type 1 and type 2 diabetes). U300 is a more concentrated form of insulin glargine (300 units/mL) proposed as an… | Jul 2015 | Recommended with restriction | 2 individuals |
| insulin glulisine Treatment of Type 1 and Type 2 diabetes mellitus in adults and children older than 12 years who require insulin for the control of hyperglycaemia. | Mar 2007 | Recommended | no section in document |
Who spoke
Australian Diabetes Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.